[HTML][HTML] Cholinesterase inhibitors as Alzheimer's therapeutics

K Sharma - Molecular medicine reports, 2019 - spandidos-publications.com
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic
syndrome of the central nervous system that causes a decline in cognitive function and …

Development of multifunctional molecules as potential therapeutic candidates for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis in the …

MG Savelieff, G Nam, J Kang, HJ Lee, M Lee… - Chemical …, 2018 - ACS Publications
Neurodegenerative diseases pose a substantial socioeconomic burden on society.
Unfortunately, the aging world population and lack of effective cures foreshadow a negative …

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies

P Sharma, P Srivastava, A Seth, PN Tripathi… - Progress in …, 2019 - Elsevier
AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions

A Abeysinghe, R Deshapriya, C Udawatte - Life sciences, 2020 - Elsevier
Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …

The state of the art on acetylcholinesterase inhibitors in the treatment of Alzheimer's disease

I Vecchio, L Sorrentino, A Paoletti… - Journal of Central …, 2021 - journals.sagepub.com
Alzheimer's disease (AD) is a chronic disabling disease that affects the central nervous
system. The main consequences of AD include the decline of cognitive functions and …

[HTML][HTML] Alzheimer's disease pharmacotherapy in relation to cholinergic system involvement

GD Stanciu, A Luca, RN Rusu, V Bild… - Biomolecules, 2019 - mdpi.com
Alzheimer's disease, a major and increasing global health challenge, is an irreversible,
progressive form of dementia, associated with an ongoing decline of brain functioning. The …

[HTML][HTML] A molecular approach in drug development for Alzheimer's disease

S Agatonovic-Kustrin, C Kettle, DW Morton - Biomedicine & …, 2018 - Elsevier
An increase in dementia numbers and global trends in population aging across the world
prompts the need for new medications to treat the complex biological dysfunctions, such as …

[HTML][HTML] Combination drug therapy for the management of Alzheimer's disease

MT Kabir, MS Uddin, AA Mamun, P Jeandet… - International Journal of …, 2020 - mdpi.com
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Even though the
number of AD patients is rapidly growing, there is no effective treatment for this …

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

Q Li, H Yang, Y Chen, H Sun - European journal of medicinal chemistry, 2017 - Elsevier
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders with
notable factor of dysfunction in cholinergic system. Low ACh level can be observed in the …

Multi-target design strategies for the improved treatment of Alzheimer's disease

P Zhang, S Xu, Z Zhu, J Xu - European journal of medicinal chemistry, 2019 - Elsevier
Alzheimer's disease (AD) is a multifactorial syndrome resulting in profound misery and
poses a substantial burden on human health, economy, and society throughout the world …